Early cytogenetic and molecular responses achieved with ponatinib was significantly linked with better long-term progression-free survival and overall survival in patients with highly resistant, pretreated chronic-phase chronic myeloid leukemia.
Hagop M. Kantarjian, MD, discusses the predictive value of early landmark cytogenetic or molecular responses to ponatinib in heavily pretreated patients with chronic-phase chronic myeloid leukemia.
Dr. Hagop Kantarjian, whose life work has transformed research, diagnosis and treatment of leukemia, also expands cancer research networks and collaboration in the Middle East.
Dr. Hagop Kantarjian, whose life work has transformed research, diagnosis and treatment of leukemia, also expands cancer research networks and collaboration in the Middle East.